Tag: IIH
Acandis gains German regulatory approval to launch SONIC study evaluating Silance...
Acandis has announced that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to initiate the SONIC study...
Long-term data support durability of River stent in IIH treatment
Serenity Medical, a NeuroTechnology Investors (NTI) portfolio company, has announced four-to-five-year results from the RIVER study, which is described as the first multicentre evaluation...
Serenity gains “landmark” US FDA humanitarian device exemption for novel cerebral...
Serenity Medical, a NeuroTechnology Investors (NTI) portfolio company, has today announced a “landmark” US Food and Drug Administration (FDA) humanitarian device exemption (HDE) approval for its novel...
“First-of-its-kind” study demonstrates Monopoint system’s utility in IIH treatment
Route 92 Medical has announced the results of a “first-of-its-kind” multicentre study—published recently in Stroke: Vascular and Interventional Neurology—demonstrating the utility of the company’s...
Safety of venous sinus stenting in IIH patients established via one-year...
A prospective study has established the safety of venous sinus stenting (VSS) using a novel device in idiopathic intracranial hypertension (IIH) patients who have...
Meta-analysis deems venous sinus stenting a safe and effective option in...
A meta-analysis published recently in the Journal of the Neurological Sciences has concluded that venous sinus stenting (VSS) appears to be a safe and...
